Administration of vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in rats

Journal of Nephrology

Volumn 25, Issue 3, 2012, Pages 410-417

  Nematbakhsh, Mehdi ^a,b   Ashrafi, Farzaneh ^a,b   Safari, Tahereh ^a,b   Talebi, Ardeshir ^a,b   Nasri, Hamid ^a,b   Mortazavi, Mojgan ^a,b   Khazaei, Mehdi ^b   Baradaran Mahdavi, Mohammad Mehdi ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cisplatin; Losartan; Nephrotoxicity; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; CISPLATIN; CREATININE; LOSARTAN; MALONALDEHYDE; NITROGEN; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CISPLATIN INDUCED NEPHROTOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; HISTOPATHOLOGY; IRAN; KIDNEY INJURY; MALE; NONHUMAN; RAT; SCORING SYSTEM; SERUM OSMOLALITY; UREA NITROGEN BLOOD LEVEL; URINE OSMOLALITY;

ANIMALS; BLOOD UREA NITROGEN; BODY WEIGHT; CISPLATIN; CREATININE; CYTOPROTECTION; DISEASE MODELS, ANIMAL; KIDNEY; KIDNEY DISEASES; LOSARTAN; MALE; MALONDIALDEHYDE; NITRITES; OSMOLAR CONCENTRATION; PROTECTIVE AGENTS; RATS; RATS, WISTAR; VITAMIN E;

EID: 84857603397     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000018     Document Type: Article

References (43)

1. Hanigan MH, Devarajan P. Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther. 2003;1:47-61.
2. Jiang M, Wang CY, Huang S, Yang T, Dong Z. Cisplatininduced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway. Am J Physiol Renal Physiol. 2009;296(5):F983-F993.
3. Fatima S, Yusufi AN, Mahmood R. Effect of cisplatin on renal brush border membrane enzymes and phosphate transport. Hum Exp Toxicol. 2004;23(12):547-554.
4. Liu L, Yang C, Herzog C, Seth R, Kaushal GP. Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity. Biochem Pharmacol. 2010;79(2):137-146.
5. Yano T, Itoh Y, Matsuo M, Kawashiri T, Egashira N, Oishi R. Involvement of both tumor necrosis factor-alpha-induced necrosis and p53-mediated caspase-dependent apoptosis in nephrotoxicity of cisplatin. Apoptosis. 2007;12(10): 1901-1909.
6. Zhang JG, Lindup WE. Cisplatin nephrotoxicity: decreases in mitochondrial protein sulphydryl concentration and calcium uptake by mitochondria from rat renal cortical slices. Biochem Pharmacol. 1994;47(7):1127-1135.
7. Basnakian AG, Apostolov EO, Yin X, Napirei M, Mannherz HG, Shah SV. Cisplatin nephrotoxicity is mediated by deoxyribonuclease I. J Am Soc Nephrol. 2005;16(3):697-702.
8. De Martinis BS, Bianchi MD. Effect of vitamin C supplementation against cisplatin-induced toxicity and oxidative DNA damage in rats. Pharmacol Res. 2001;44(4):317-320.
9. Saad AA, Youssef MI, El-Shennawy LK. Cisplatin induced damage in kidney genomic DNA and nephrotoxicity in male rats: the protective effect of grape seed proanthocyanidin extract. Food Chem Toxicol. 2009;47(7):1499-1506.
10. Ajith TA, Usha S, Nivitha V. Ascorbic acid and alpha-tocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice: a comparative study. Clin Chim Acta. 2007;375(1-2): 82-86.
11. Deegan PM, Nolan C, Ryan MP, Basinger MA, Jones MM, Hande KR. The role of the renin-angiotensin system in cisplatin nephrotoxicity. Ren Fail. 1995;17(6):665-674.
12. Saleh S, Ain-Shoka AA, El-Demerdash E, Khalef MM. Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. Chemotherapy. 2009; 55(6):399-406.
13. Tarladacalisir YT, Kanter M, Uygun M. Protective effects of vitamin C on cisplatin-induced renal damage: a light and electron microscopic study. Ren Fail. 2008;30(1):1-8.
14. Ajith TA, Abhishek G, Roshny D, Sudheesh NP. Co-supplementation of single and multi doses of vitamins C and E ameliorates cisplatin-induced acute renal failure in mice. Exp Toxicol Pathol. 2009;61(6):565-571.
15. Appenroth D, Fröb S, Kersten L, Splinter FK, Winnefeld K. Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch Toxicol. 1997;71(11):677-683.
16. Atasayar S, Gürer-Orhan H, Orhan H, Gürel B, Girgin G, Ozgüneş H. Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats. Exp Toxicol Pathol. 2009;61(1):23-32.
17. Sugihara K, Gemba M. Modification of cisplatin toxicity by antioxidants. Jpn J Pharmacol. 1986;40(2):353-355.
18. Fang YZ, Yang S, Wu G. Free radicals, antioxidants, and nutrition. Nutrition. 2002;18(10):872-879.
19. Wang X, Quinn PJ. Vitamin E and its function in membranes. Prog Lipid Res. 1999;38(4):309-336.
20. Wang X, Quinn PJ; Xiaoyuan Wang, Peter J. Quinn. The location and function of vitamin E in membranes [review]. Mol Membr Biol. 2000;17(3):143-156.
21. Naziroglu M, Karaoglu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicolog. 2004;195(2-3):221-230.
22. Ullman J, Eriksson S, Rundgren M. Losartan increases renal blood flow during isoflurane anesthesia in sheep. Acta Anaesthesiol Scand. 2001;45(9):1168-1175.
23. Ullman J, Eriksson S, Rundgren M. Effects of losartan, prazosin and a vasopressin V1-receptor antagonist on renal and femoral blood flow in conscious sheep. Acta Physiol Scand. 2001;171(1):99-104.
24. Dukacz SA, Kline RL. Differing effects of enalapril and losartan on renal medullary blood flow and renal interstitial hydrostatic pressure in spontaneously hypertensive rats. J Hypertens. 1999;17(9):1345-1352.
25. Thamilselvan S, Menon M. Vitamin E therapy prevents hyperoxaluria-induced calcium oxalate crystal deposition in the kidney by improving renal tissue antioxidant status. BJU Int. 2005;96(1):117-126.
26. Coskun O, Armutcu F, Kanter M, Kuzey GM. Protection of endotoxin-induced oxidative renal tissue damage of rats by vitamin E or/and EGb 761 treatment. J Appl Toxicol. 2005; 25(1):8-12.
27. Selliah S, de Mel T, Hewamadduma CA, de Tissera A. Protective effective of vitamin E in kidney storage solution on renal tissue metabolism in rats. Ceylon Med J. 1995;40(3): 97-100.
28. Yagi K. Simple assay for the level of total lipid peroxides in serum or plasma. Methods Mol Biol. 1998;108:101-106.
29. Armstrong D, Browne R. The analysis of free radicals, lipid peroxides, antioxidant enzymes and compounds related to oxidative stress as applied to the clinical chemistry laboratory. Adv Exp Med Biol. 1994;366:43-58.
30. Ammer U, Natochin Y, David C, Rumrich G, Ullrich KJ. Cisplatin nephrotoxicity: site of functional disturbance and correlation to loss of body weight. Ren Physiol Biochem. 1993;16(3):131-145.
31. Ohno T, Kato S, Wakatsuki M, et al. Incidence and temporal pattern of anorexia, diarrhea, weight loss, and leukopenia in patients with cervical cancer treated with concurrent radiation therapy and weekly cisplatin: comparison with radiation therapy alone. Gynecol Oncol. 2006;103(1):94-99.
32. Endo Y, Kanbayashi H. Modified rice bran beneficial for weight loss of mice as a major and acute adverse effect of Cisplatin. Pharmacol Toxicol. 2003;92(6):300-303.
33. Miya T, Goya T, Yanagida O, Nogami H, Koshiishi Y, Sasaki Y. The influence of relative body weight on toxicity of combination chemotherapy with cisplatin and etoposide. Cancer Chemother Pharmacol. 1998;42(5):386-390.
34. Ochoa B, Bobadilla N, Arrellín G, Herrera LA. S-Adenosyl-Lmethionine increases serum BUN and creatinine in cisplatintreated mice. Arch Med Res. 2009;40(1):54-58.
35. Abbasciano V, Mazzotta D, Vecchiatti G, Tassinari D, Nielsen I, Sartori S. Changes in serum, erythrocyte, and urinary magnesium after a single dose of cisplatin combination chemotherapy. Magnes Res. 1991;4(2):123-125.
36. Hegedüs L, van der Vijgh WJ, Klein I, Kerpel-Fronius S, Pinedo HM. Chemical reactivity of cisplatin bound to human plasma proteins. Cancer Chemother Pharmacol. 1987;20(3): 211-212.
37. Leung EL, Fraser M, Fiscus RR, Tsang BK. Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance. Br J Cancer. 2008;98(11):1803-1809.
38. Tang CH, Grimm EA. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem. 2004;279(1): 288-298.
39. Wink DA, Cook JA, Christodoulou D, et al. Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin. Nitric Oxide. 1997;1(1):88-94.
40. Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G, et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced nonsmall cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer. 2010;10(1):50.
41. Nanji AA, Mikhael NZ, Stewart DJ. Hypoalbuminemia in patients receiving cisplatin: correlation between liver platinum and decrease in serum albumin. Oncology. 1986;43(1):33-35.
42. Polycarpe E, Arnould L, Schmitt E, et al. Low urine osmolarity as a determinant of cisplatin-induced nephrotoxicity. Int J Cancer. 2004;111(1):131-137.
43. Aktoz T, Aydogdu N, Alagol B, Yalcin O, Huseyinova G, Atakan IH. The protective effects of melatonin and vitamin E against renal ischemia-reperfusion injury in rats. Ren Fail. 2007;29(5):535-542.